Sai Life Sciences' Q1 FY 2025-26 Quarter Results

Result Summary

• Sai Life Sciences Ltd reported a 14.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 75.9%.
• Its expenses for the quarter were up by 16.1% QoQ and 39.1% YoY.
• The net profit increased 7.7% QoQ and decreased 547.9% YoY.
• The earnings per share (EPS) of Sai Life Sciences Ltd stood at 2.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sai Life Sciences Ltd is a company primarily engaged in the pharmaceutical industry, offering a range of services that can include drug discovery, development, and manufacturing. The company operates in a sector known for its dynamic nature, driven by innovation and regulatory frameworks. As a significant player in the market, Sai Life Sciences focuses on providing high-quality pharmaceutical solutions, often collaborating with global pharmaceutical companies. Recent major developments in the pharma industry may include advancements in biotechnology and personalized medicine, although specific recent developments for Sai Life Sciences are not available in the provided data.

Revenue

For the quarter ending in Q1FY26, Sai Life Sciences Ltd reported a total income of ₹506.32 crores, marking a notable increase from ₹442.55 crores in Q4FY25 and significantly higher than ₹287.84 crores in Q1FY25. The quarter-over-quarter (QoQ) growth stands at 14.4%, while the year-over-year (YoY) growth is an impressive 75.9%. These metrics indicate a substantial rise in revenue generation over both the previous quarter and the same quarter last year. The revenue growth reflects the company's increasing capacity to generate income, possibly due to expanded operations or increased demand for its services.

Profitability

In Q1FY26, Sai Life Sciences Ltd achieved a profit before tax of ₹80.75 crores, compared to ₹76.05 crores in Q4FY25 and a loss of ₹18.06 crores in Q1FY25. The profit after tax for the same period was ₹60.46 crores, up from ₹56.13 crores in the previous quarter and a loss of ₹13.50 crores in the year-ago period. The QoQ growth in profit before tax is 6.2%, and YoY growth is significantly higher due to the transition from a loss to a profit. The effective tax paid in Q1FY26 was ₹20.29 crores. Earnings per share (EPS) in this quarter were ₹2.80, reflecting a decline from ₹3.10 in Q4FY25, and a marked improvement from zero in Q1FY25 due to the transition from loss to profit.

Operating Metrics

Total expenses for Sai Life Sciences Ltd in Q1FY26 were ₹425.57 crores, showing an increase from ₹366.49 crores in Q4FY25 and ₹305.90 crores in Q1FY25. This represents a 16.1% increase QoQ and a 39.1% increase YoY. The increase in expenses, while significant, coincides with the company's revenue growth, suggesting operational expansion or increased input costs. The company's profitability metrics indicate a positive trajectory over the past year, with improvements in both gross and net profit margins evidenced by the transition from losses to profits. However, the EPS decline QoQ suggests a need to consider operational efficiency and cost management in future assessments.